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bstract
ntroduction: Significant preclinical evidence exists for a synergistic interaction between the opioid and the serotonin systems in determining
lcohol consumption. Naltrexone, an opiate receptor antagonist, is approved for the treatment of alcohol dependence. This double-blind placebo-
ontrolled study examined whether the efficacy of naltrexone would be augmented by concurrent treatment with sertraline, a selective serotonin
eceptor uptake inhibitor (SSRI).
ethods: One hundred and thirteen participants meeting DSM IV alcohol dependence criteria, who were abstinent from alcohol between 5 and
0 days, were randomly assigned to receive one of two treatments at two sites. One group received naltrexone 12.5 mg once daily for 3 days, 25 mg
nce daily for 4 days, and 50 mg once daily for the next 11 weeks, together with placebo sertraline. The other group received naltrexone as outlined
nd simultaneously received sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks. Both groups received group
elapse prevention psychotherapy on a weekly basis.
esults: Compliance and attendance rates were comparable and high. The groups did not differ on the two primary outcomes, time to first drink
nd time to relapse to heavy drinking, or on secondary treatment outcomes. With the exception of sexual side effects which were more common
n the combination group, most adverse events were similar for the two conditions.
onclusions: As the doses are tested in combination with specialized behavioral therapy, this study does not provide sufficient evidence for the
ombined use of sertraline and naltrexone above naltrexone alone.
2008 Elsevier Ireland Ltd.
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. Introduction
The FDA approval of the opioid antagonist naltrexone on the
asis of two successful clinical trials (O’Malley et al., 1992;
olpicelli et al., 1992) opened a new vista for the use of phar-
acotherapy in conjunction with psychotherapy to treat alcohol
ependent individuals. With the publication of further positive
rials of naltrexone (for reviews, see Kranzler and Van Kirk,
001; Pettinati et al., 2006) including a large NIH sponsored
ulti-site study (Anton et al., 2006), it has become clear that
altrexone has a useful place in the range of treatment options.
∗ Corresponding author at: St. Patrick’s Hospital, James Street, Dublin 8,
reland. Tel.: +353 1 2493523; fax: +353 1 6798865.
E-mail address: cfarren@stpatsmail.com (C.K. Farren).
b
(
s
g
(
a
r
r
376-8716 © 2008 Elsevier Ireland Ltd.
oi:10.1016/j.drugalcdep.2008.06.006
Open access under CC BY-NC-ND license.ogy
trategies to further enhance treatment response are being exam-
ned, including long acting naltrexone formulations (Garbutt et
l., 2005; Kranzler et al., 2004; O’Malley et al., 2007) and com-
ination therapies (e.g., Anton et al., 2006; Johnson et al., 2000;
eifer et al., 2003).
Several lines of research suggest that selective serotonin
euptake inhibitors (SSRIs) may be useful for augmenting nal-
rexone response. The serotonin system has long been found to
e abnormal in preclinical and clinical studies of alcoholism
LeMarquand et al., 1994a,b). Preclinical models have also
hown that the combination of an SSRI and naltrexone results in
reater suppression of drinking compared to either drug alone
Zink et al., 1997; Rezvani et al., 2000). Potential additive effects
re also suggested by preclinical work showing that fluoxetine
educes stress-induced reinstatement of drinking and naltrexone
educes alcohol reinstatement (Le et al., 1999). Although most
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linical trials find that SSRIs are ineffective in treating alcohol
ependence in unselected patients (Mann, 2004), some SSRIs
ay have therapeutic benefit in at least a typology-based sub-
roup (Kranzler et al., 1996; Pettinati et al., 2001; Tiihonen et
l., 1996). For example, Pettinati et al. (2001) found increased
bstinence with the use of 200 mg of sertraline in Type A (less
evere) alcohol dependence. Finally, preliminary evidence from
mall open label studies combining naltrexone with agents tar-
eting the serotonin system suggested benefit in non-depressed
lcohol dependent patients (Farren et al., 2000; Johnson et al.,
000).
We thus examined the addition of the SSRI sertra-
ine to naltrexone, in combination with standard cognitive
ehavioral psychotherapy, in a 12-week double-blind placebo-
ontrolled trial in non-depressed alcohol dependent individuals.
xploratory analyses examined whether age of onset (early ver-
us late) influenced the results.
. Materials and methods
The study was carried out at two sites, Yale University School of Medicine
n New Haven, CT and Mount Sinai School of Medicine in New York City. The
rotocol was approved by the local IRBs and all participants provided informed
onsent.
.1. Medication
Participants were randomly assigned to one of two medication groups. The
altrexone only group received naltrexone 12.5 mg daily for 3 days, 25 mg
aily for 4 days, and 50 mg daily for the next 11 weeks, together with placebo
ertraline. The combination group received the same naltrexone regimen, but
imultaneously received sertraline 50 mg daily for 2 weeks, followed by 100 mg
aily for 10 weeks. Groups were randomized within site according to a com-
uterized schedule. Pill counts were performed weekly for the first 2 weeks,
nd biweekly for the next 10 weeks. Participants also self-reported medication
ompliance. Riboflavin was added to the sertraline/placebo capsules by the dis-
ensing pharmacy and urinary fluorescence was measured at the same frequency
Del Boca et al., 1996).
.2. Therapy
Subjects received weekly group relapse prevention psychotherapy (Project
atch Research Group, 1997) for 12 weeks. Therapy sessions were conducted
y masters or doctoral level psychotherapists and subjects were encouraged to
ttend Alcoholics Anonymous meetings.
.3. Recruitment
Potential participants responded to local advertisements. Subjects ranged in
ge from 19 to 64 and met DSM-IV criteria for alcohol dependence (Spitzer and
illiams, 1992). Between 5 and 30 days of alcohol abstinence prior to medica-
ion administration was required. Subjects were excluded if they met criteria for
urrent abuse or dependence on any substance other than nicotine or alcohol,
ad a current Axis I disorder in addition to alcohol dependence (including major
epression), or reported any past illicit opiate use. Other exclusions were sig-
ificant liver disease (AST or ALT >300% of upper limit of normal or bilirubin
110% of upper limit of normal), a positive BAL during evaluation, or any major
hysical illness..4. Assessments
The Addiction Severity Index (ASI) (McLellan et al., 1980), the Obses-
ive Compulsive Drinking Scale (OCDS) (Anton et al., 1996), the Beck
T
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epression Inventory (BDI) (Beck et al., 1961), and the Time-line Follow-
ack Interview (TLFB) (Sobell et al., 1988) were completed at baseline.
lood tests including serum aspartate aminotransferase (AST) and gamma-
lutamyltransferase (GGT) were obtained at baseline, 4 and 12 weeks.
he following assessments were made weekly for the first 2 weeks and
iweekly subsequently: the OCDS, the BDI, the TLFB, and a side-effects
cale.
The primary outcomes included time to first drink and time to first relapse to
eavy drinking (with relapse defined as 5 drinks in 1 day for men, and 4 drinks
n 1 day for women). Percent days abstinent, number of drinks per drinking day
or drinkers, change in Obsessive Compulsive Drinking Scale total scores, and
LT and GGT change from baseline were secondary outcomes.
.5. Data analysis
Data were analyzed using SAS Version 9.1 (SAS Institute, Inc., Cary,
C). The primary analysis was conducted on the intention to treat sam-
le (n= 111). The survival analysis with maximum likelihood method was
sed to analyze the time-to-event outcomes. Missing data were censored.
ixed models were used for repeated outcomes and Analysis of Variance
as applied to all other continuous outcomes. Site was a covariate in the
nalyses.
. Results
.1. Subject characteristics
The study was completed over 5 years. A total of 605 patients
299 Yale, 306 Mt. Sinai) were screened to produce randomiza-
ion of 113 subjects (41 Yale, 72 Mt. Sinai) over the two sites. The
ajority of patients were ineligible for randomization because
f the presence of depressive symptoms or failure to follow up.
wo subjects were subsequently excluded from the intention
o treat analysis at Mt. Sinai because they failed to meet entry
riteria yielding a final sample of 111. Although participants
t the two sites were similar in most characteristics, the Mt.
inai group had a higher percentage of participants with high
chool education or greater (98.5% versus 78.1%, p< .001), had
ewer Whites (61.2% versus 87.8%, p< .01), and reported fewer
aseline drinks per drinking day (5.7 ± 2.90 versus 10.0 ± 6.0,
< 0.01).
Table 1 presents the baseline characteristics of the sample.
ifty-seven participants received naltrexone with sertraline and
4 subjects received naltrexone and placebo. Twenty-three of
he combination group did not complete, with 11 lost to fol-
ow up, 6 having poor compliance, and 6 due to side effects.
ourteen of the placebo group did not complete with 10 being
ost to follow up, 2 having poor compliance, and 2 due to side
ffects.
.2. Compliance
During treatment, medication compliance rates by pill count
nd urinary riboflavin were similar. The number of therapy
essions attended was equivalent, with 7.3 (±0.5) for the
ombination group and 8.5 (±0.3) for the placebo group.
he number and percentage of each group with complete
rinking data was also not significantly different between the
ombination group (42, 73.7%) and the placebo group (44,
1.5%).
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Table 1
Baseline characteristics and drinking outcomes [mean ± S.D.]
Characteristic Naltrexone + Sertraline (N= 57) Naltrexone + Placebo (N= 54)
Age 41.5 (9.55) 44.9 (9.68)
Male gender (%) 80.7 83.3
Race or ethnic group (%)
White 71.4 71.2
Black 12.5 11.5
Hispanic 10.7 11.5
Other 5.4 5.8
Marital status
% Married or living with partner 33.9 46.2
High school or greater 91.1 90.4
Age of onset of alcohol-related problems 30.8 (10.09) 33.3 (8.72)
% Days abstinent 29.3 (19.13) 25.6 (18.66)
Drinks per drinking day in previous 90 days 7.3 (4.82) 7.4 (4.78)
ALT 7.8 (5.72) 7.3 (5.30)
GGT 92.7 (122.39) 118.0 (208.76)
Drinking outcomes (%)
Drinks per drinking day for drinkersa 5.3 (4.06) 4.3 (4.29)
Drinks per drinking day for all subjects 2.8 (3.95) 3.0 (4.09)
Percent days abstinent 79.2 (30.48) 84.5 (17.47)
OCDS totalb 7.4 (5.50) 7.7 (6.23)
GGT change from baseline 26.4 (44.70) 60.5 (170.88)
ALT change from baseline 4.0 (33.9) 10.3 (23.8)
N inking
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ro significant differences between groups in their baseline characteristics or dr
a N= 28 for naltrexone + sertraline and N= 37 for naltrexone + placebo.
b Mixed model.
.3. Outcomes
Time to the first day of drinking was longer, although not
tatistically different (p= 0.10; Fig. 1) for the combination
roup (49.1% abstinent) compared to the naltrexone alone group
31.5% abstinent). There was no significant difference between
roups in time to first relapse to heavy drinking (p= 0.13), time
o second drink (p= 0.13), or in percent days abstinent (p= 0.19).
mong those subjects who drank (n= 64), the groups were sim-
ig. 1. Time to first drink for naltrexone with sertraline (N= 57) and naltrexone
ith placebo (N= 54) groups. With missing data as censored, the analysis showed
time to first drinking day for the naltrexone plus sertraline group as 29 days
50.88% censored) vs. 18 (33.33% censored) for the naltrexone alone group,
= 0.10.
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lar on drinks per drinking day (p= 0.19). There was also no
ignificant difference in change in GGT (p= 0.30), ALT scores
p= 0.31), BDI or OCDS scores.
Rates of the majority of reported side effects, including dis-
upted sleep, decreased sex drive, low energy, nausea, headache
nd altered appetite were not significantly different between
roups. There were more reported sexual side effects in the com-
ination group (68% versus 24%, p< 0.001). The incidence of
eported side effects peaked at week one in both groups (data not
hown), with the frequency and intensity of most side effects,
xcept sexual side effects, declining over time.
Exploratory analyses of outcomes by subtype of alcoholism
ere also completed with age of onset used as the criterion for
lassifying participants as having Type I (late onset at age 25 or
lder) or Type II (early onset prior to age 25) alcoholism. There
ere 81 Type I (75.7%) and 26 Type II (24.3%) individuals
ith 4 patients unassigned due to missing data on age of onset.
he previous models of drinking outcomes were repeated exam-
ning the main and interactive effects of medication group and
ypology. All main effects and interactions were non-significant.
. Discussion
This placebo-controlled study did not support the hypothesis
hat sertraline would augment the efficacy of naltrexone in com-
ination with group relapse prevention therapy. Although the
ombination group had a somewhat higher rate of abstinence
ompared to the naltrexone only group, this difference was not
tatistically significant. Moreover, there was no added benefit
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f the combined treatment in terms of prevention of relapse
o heavy drinking or on any other secondary outcomes. The
egative results are in contrast to our preliminary study which
ompared two groups of matched patients treated open label
ith either the combination or naltrexone monotherapy (Farren
t al., 2000), but are consistent with a recent placebo-controlled
tudy conducted in Alaska (O’Malley et al., 2008).
The decision to recruit non-depressed individuals with alco-
ol dependence was made on the basis of the preclinical and
linical evidence for the general involvement of the serotonin
ystem in alcoholism (LeMarquand et al., 1994a). In retrospect,
he choice of a non-depressed group may have made a posi-
ive outcome less likely, as one prior study noted a benefit of
erotonin medications in depressed alcohol dependent patients
Cornelius et al., 1997), although other studies have not (Moak
t al., 2003; Kranzler et al., 2006). Type A alcohol dependent
atients have been shown to benefit from SSRI’s in prior research
Pettinati et al., 2000), and we conducted exploratory analyses
xamining alcoholism typology (early versus late onset) as a
redictor of response, but did not find an advantage for the com-
ination of sertraline and naltrexone in Type 1 or early onset
atients. Possible explanations include the small sample size
nd the fact that all patients received active naltrexone, an effec-
ive treatment that may have obscured any potential benefit of
ertraline for this subgroup. Perhaps analyses using a typology
ased on severity rather than age of onset might have had dif-
erent results; unfortunately, we did not have the data needed to
lassify participants according the Babor typology (Pettinati et
l., 2001; Kranzler et al., 1996).
A different dose of sertraline may have been more effective.
or example, Pettinati et al. (2000) reported positive results using
00 mg daily of sertraline. Our study was initiated prior to that
eport, and the 100 mg dose was selected based on the results
f a pilot study (Farren et al., 2000), preclinical studies (Gill et
l., 1988; Higgins et al., 1992; Rezvani et al., 2000), and the
ossible escalation of side effects with higher doses of sertra-
ine, particularly in combination with naltrexone. In the current
tudy, although only sexual side effects were higher in the com-
ination group, 40.3% (23/57) of participants in the combination
roup failed to complete treatment compared to 25.9% (14/54)
f participants in the naltrexone only group. In addition, dis-
ontinuation due to adverse events was more common in the
ombination group (6 versus 2), suggesting that the potential for
ncreased efficacy with a higher sertraline dose might be com-
romised by poorer tolerability, at least in combination with
altrexone. There is no evidence in the extant literature for a
harmacokinetic interaction between the two compounds that
ight alter either’s blood levels or side effect profiles.
In conclusion, the study’s findings do not support the use of
00 mg of sertraline to augment the efficacy of naltrexone for the
reatment of non-depressed alcohol dependent patients. Other
oses, other induction schedules or durations of treatment may
ave been more effective. Future trials of combination drug ther-
pies should consider incorporating a less intensive behavioral
latform, as there may be a ceiling effect when pharmacothera-
ies are tested with intensive psychotherapy. In the present study,
ll participants received naltrexone and CBT therapy, both effec-Dependence 99 (2009) 317–321
ive treatments (Anton et al., 2006), and both groups showed
ubstantial improvements.
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